SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism

Tauber, M; Ester, W; Auriol, F; Molinas, C; Fauvel, J; Caliebe, J; Nugent, T; Fryklund, L; Ranke, MB; Savage, MO; et al. Tauber, M; Ester, W; Auriol, F; Molinas, C; Fauvel, J; Caliebe, J; Nugent, T; Fryklund, L; Ranke, MB; Savage, MO; Clark, AJ; Johnston, LB; Hokken-Koelega, AC; NESTEGG group (2007) GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism. CLINICAL ENDOCRINOLOGY, 67 (3). 457 - 461. ISSN 0300-0664 https://doi.org/10.1111/j.1365-2265.2007.02911.x
SGUL Authors: Clark, Adrian John L

[img]
Preview
PDF Published Version
Available under License St George's repository terms & conditions.

Download (161kB) | Preview

Abstract

Objective: The polymorphic deletion of exon 3 of the GH receptor (d3-GHR) has recently been linked to the magnitude of growth response to recombinant human GH (rhGH) therapy in short children with or without GH deficiency. We investigated this association in a large multinational cohort from the Network of European Studies of Genes in Growth (NESTEGG), comprising short children born small for gestational age (SGA). Design: The study included short prepubertal SGA children treated with rhGH for 1 or 2 years. Population: Two hundred and forty white Caucasian SGA children (138 male, 102 female) aged 6·6 ± 2·3 years with a height at –3·0 ± 0·7 SDS at start of rhGH treatment; 193 ethnically matched controls. Methods: The GHR polymorphism (fl/fl, fl/d3 or d3/d3) was genotyped by polymerase chain reaction (PCR) multiplex assay. Growth velocity (G/V) in cm/year and changes in GV during the first and second year of rhGH treatment were evaluated. Results: The change in GV was significantly greater in SGA children carrying one or two copies of the d3-GHR allele (P = 0·038 for the first year and P = 0·041 for the second year of GH treatment), but the change in height was not significantly different. Birthweight was significantly lower in SGA children with the d3/d3 genotype than in SGA children with the fl/fl genotype (P = 0·034) and in those with the fl/d3 genotype (P = 0·016). Conclusion: Our data, based on a large cohort, showed that the exon 3 GHR polymorphism is associated with responsiveness to rhGH treatment in SGA children with short stature.

Item Type: Article
Additional Information: © 2007 The Authors Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2·5
Keywords: Body Height, Carrier Proteins, Child, Child, Preschool, Cohort Studies, Drug Resistance, Exons, Female, Genotype, Growth Disorders, Human Growth Hormone, Humans, Infant, Newborn, Infant, Small for Gestational Age, Internationality, Male, Phenotype, Polymorphism, Genetic, Treatment Outcome, Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, ENDOCRINOLOGY & METABOLISM, FOR-GESTATIONAL-AGE, GROWTH-HORMONE RECEPTOR, WEIGHT HEIGHT VELOCITY, DEFICIENCY, STANDARDS, MATURITY, BIRTH, FOR-GESTATIONAL-AGE, GROWTH-HORMONE RECEPTOR, WEIGHT HEIGHT VELOCITY, DEFICIENCY, STANDARDS, MATURITY, BIRTH, 1103 Clinical Sciences, 1114 Paediatrics And Reproductive Medicine
Journal or Publication Title: CLINICAL ENDOCRINOLOGY
ISSN: 0300-0664
Related URLs:
Dates:
DateEvent
1 September 2007Published
Web of Science ID: WOS:000248978000021
URI: http://openaccess.sgul.ac.uk/id/eprint/107145
Publisher's version: https://doi.org/10.1111/j.1365-2265.2007.02911.x

Actions (login required)

Edit Item Edit Item